Christopher Missling
Directeur Général chez ANAVEX LIFE SCIENCES CORP.
Fortune : 5 M $ au 31/05/2024
Profil
Christopher U.
Missling is currently the President, CEO, Secretary & Director at Anavex Life Sciences Corp.
He previously held positions as the Chief Financial Officer at ImmunoGen, Inc., CFO & Senior Vice President-Strategic Operations at Curis, Inc., Head-Financial Planning at Aventis, Inc., and Head-Healthcare Investment Banking at Brimberg & Co. He has a graduate and doctorate degree from Ludwig-Maximilians-Universität München, an MBA from WHU-Otto Beisheim School of Management, and another MBA from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/03/2024 | 1 250 210 ( 1,48% ) | 5 M $ | 31/05/2024 |
Postes actifs de Christopher Missling
| Sociétés | Poste | Début |
|---|---|---|
| ANAVEX LIFE SCIENCES CORP. | Directeur Général | 05/07/2013 |
Anciens postes connus de Christopher Missling
| Sociétés | Poste | Fin |
|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - |
| IMMUNOGEN, INC. | Directeur Financier/CFO | - |
Brimberg & Co.
 Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Corporate Officer/Principal | - |
| CURIS, INC. | Directeur Financier/CFO | - |
Formation de Christopher Missling
| Ludwig-Maximilians-Universität München | Doctorate Degree |
| WHU-Otto Beisheim School of Management | Masters Business Admin |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CURIS, INC. | Health Technology |
| ANAVEX LIFE SCIENCES CORP. | Health Technology |
| Entreprise privées | 3 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
| Aventis, Inc. | |
Brimberg & Co.
Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Finance |
